NASDAQ : SLXN
Silexion Therapeutics Corp — Key statistics
Healthcare · Biotechnology · Israel
Last price 0.1452 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 807.35K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 824,586 |
| Enterprise Value | 5,586 |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 5.56M |
| Shares Outstanding | 5.56M |
| Shares Change (YoY) | +2,257.95% |
| Shares Change (QoQ) | +112.78% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 0.57% |
| Float | 5.56M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 18.35 |
| P/TBV Ratio | 18.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.94 |
| Quick Ratio | 0.56 |
| Debt / Equity | 32.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,086.69 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -5,232.22% |
| Weighted Average Cost of Capital (WACC) | 1.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$997,000 |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.30 |
| 52-Week Price Change | -99.55% |
| 50-Day Moving Average | 0.28 |
| 200-Day Moving Average | 6.57 |
| Relative Strength Index (RSI) | 32.95 |
| Average Volume (20 Days) | 1,427,705 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 162,704 |
| Short Previous Month | 4.93M |
| Short % of Shares Out | 2.93% |
| Short % of Float | 2.93% |
| Short Ratio (days to cover) | 0.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.13M |
| Pretax Income | -13.96M |
| Net Income | -13.96M |
| EBITDA | -14.12M |
| EBIT | -14.13M |
| Earnings Per Share (EPS) | -$38.75 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.23M |
| Total Debt | 1.41M |
| Net Cash | 819,000 |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 44,000 |
| Book Value Per Share | 0.01 |
| Working Capital | -235,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.43M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 12,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.43M |
| FCF Per Share | -$2.24 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2,257.95% |
| Shareholder Yield | -2,257.95% |
| Earnings Yield | -26,126.53% |
| FCF Yield | -1,539.85% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 29, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |